04/07/2026 | Carol Alencar | Sechat/Marijuana Moment

https://sechat.com.br/noticia/nos-pai-de-crianca-com-doenca-terminal-defende-reclassificacao-da-cannabis-para-avancar-pesquisas-medicas 

An emotional testimony before a congressional committee highlights how changes in cannabis classification could expand access to scientific research for rare and serious conditions

There are stories that cut through the technical debate and go straight to the heart of political decisions. That’s how a father’s testimony before a congressional committee brought to light a discussion that goes beyond regulation: the possibility of transforming the future of patients with rare diseases through science.

According to the Marijuana Moment website, the father of a child with a terminal illness stated during a hearing that reclassifying cannabis could “unlock research” focused on treating rare conditions that remain largely unexplored by medicine.

The current classification of cannabis in many countries still imposes significant barriers to clinical studies and the development of new treatments. According to the website, changing this classification could facilitate researchers’ access to the plant and expand the possibilities for scientific investigation.

Regulatory limitations, in addition to hindering scientists’ access to cannabis and its derivatives, also directly impact the funding and conduct of more robust clinical studies.

At the heart of the discussion is the reality of patients with rare diseases, who often lack established treatment options. For families living with serious diagnoses, time is a critical factor.

It was in this context that the father, while sharing his experience with his terminally ill son, emphasized the need to expand scientific avenues. Cannabis, already studied for its therapeutic potential in various conditions, emerges as a possibility still limited by regulatory barriers.

Medical cannabis and the advancement of clinical research

In recent years, interest in medical cannabis has grown globally, with studies focusing on conditions such as epilepsy, chronic pain, and neurological disorders. However, according to the website, progress in more specific areas, such as rare diseases, still depends on greater regulatory flexibility.

In this context, reclassification is seen as a measure that could facilitate the development of new research, expand access to clinical data, and encourage investment in the sector.

The debate over cannabis continues to evolve, especially in the field of health. The discussion brought before the U.S. Congress highlights how regulatory decisions can directly impact patients’ lives and the pace of scientific innovation.

Meanwhile, reports such as the one presented at the hearing reinforce the importance of integrating science, politics, and real-world experiences in the development of more effective public policies.